Q-omics provides the consensus-scored PACERR profile across patient tissues and cancer cell-line models. PACERR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PACERR is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PACERR RNA expression shows 13,815 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where PACERR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PACERR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PACERR survival associations across molecular data types. PACERR RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PACERR RNA expression–survival associations across cancer types. High PACERR expression shows unfavorable associations in KIRC, UVM, COAD, THYM and LGG, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PACERR RNA expression.
This table summarizes PACERR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PACERR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PACERR shows lower tumor expression in BRCA and higher tumor expression in THCA, HNSC, LUAD, KIRC and ESCA. The THCA box plot shows higher PACERR RNA expression in tumor versus normal tissue (log2 FC = +0.856, t-test p < 0.001).
This table shows molecular features associated with PACERR in patient tissues and cancer cell lines. In patient samples, PACERR shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
